373 related articles for article (PubMed ID: 11917507)
1. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
3. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
5. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
6. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
7. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
8. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
Heresco-Levy U; Silipo G; Javitt DC
Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096
[TBL] [Abstract][Full Text] [Related]
9. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
10. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.
Zavitsanou K; Nguyen V; Newell K; Ballantyne P; Huang XF
J Chem Neuroanat; 2008 Oct; 36(2):71-6. PubMed ID: 18640263
[TBL] [Abstract][Full Text] [Related]
11. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
Noda Y; Nabeshima T
Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
[TBL] [Abstract][Full Text] [Related]
12. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
13. The role of group I metabotropic glutamate receptors in schizophrenia.
Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
[TBL] [Abstract][Full Text] [Related]
14. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
15. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
16. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?
Farber NB; Wozniak DF; Price MT; Labruyere J; Huss J; St Peter H; Olney JW
Biol Psychiatry; 1995 Dec; 38(12):788-96. PubMed ID: 8750036
[TBL] [Abstract][Full Text] [Related]
17. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
Nishikawa T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
[TBL] [Abstract][Full Text] [Related]
18. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs.
Fumagalli F; Frasca A; Racagni G; Riva MA
Mol Pharmacol; 2008 May; 73(5):1484-90. PubMed ID: 18250147
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
[TBL] [Abstract][Full Text] [Related]
20. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]